Published in J Clin Endocrinol Metab on February 15, 2010
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid (2010) 1.68
Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid (2013) 1.46
"Adjuvant Radioactive iodine 133 ablation in papillary microcarcinoma of thyroid: Saudi Arabian experience". J Otolaryngol Head Neck Surg (2015) 1.39
The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab (2012) 1.25
Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. Thyroid (2012) 1.08
The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist (2010) 1.03
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. Front Endocrinol (Lausanne) (2012) 1.00
Appropriate and accurate diagnosis of thyroid nodules: a review of thyroid fine-needle aspiration. Int J Clin Exp Med (2013) 1.00
Prognostic biomarkers in thyroid cancer. Virchows Arch (2014) 0.95
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab (2015) 0.92
Acoustic radiation force impulse imaging: a new tool for the diagnosis of papillary thyroid microcarcinoma. Biomed Res Int (2014) 0.88
New insights in risk stratification of differentiated thyroid cancer. Curr Opin Oncol (2014) 0.79
Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis. Oncotarget (2015) 0.79
The Delayed Risk Stratification System in the Risk of Differentiated Thyroid Cancer Recurrence. PLoS One (2016) 0.79
BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients. Curr Oncol (2014) 0.78
Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131. Clujul Med (2016) 0.78
Diagnostic value of two-dimensional shear wave elastography in papillary thyroid microcarcinoma. Onco Targets Ther (2016) 0.77
Increased prevalence of chronic lymphocytic thyroiditis in Korean patients with papillary thyroid cancer. PLoS One (2014) 0.77
Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. Int J Clin Oncol (2015) 0.77
Actual incidence and clinical behaviour of follicular thyroid carcinoma: an institutional experience. ScientificWorldJournal (2014) 0.77
Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it? J Clin Endocrinol Metab (2014) 0.76
Association between prognostic factors and clinical outcome of well-differentiated thyroid carcinoma: A retrospective 10-year follow-up study. Oncol Lett (2015) 0.76
F-18 FDG-PET-CT in the Diagnostic of a Late Medullary Thyroid Carcinoma Recurrence in a Patient with Follicular-Papillary Thyroid Cancer. Case Rep Endocrinol (2014) 0.75
Papillary Thyroid Carcinoma Metastases Presenting as Ipsilateral Adrenal Mass and Renal Cyst. Urol Case Rep (2015) 0.75
1.5-2 cm tumor size was not associated with distant metastasis and mortality in small thyroid cancer: A population-based study. Sci Rep (2017) 0.75
Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma. Oncotarget (2016) 0.75
Cytological diagnosis of follicular carcinoma thyroid metastasis in pelvic muscles-a rare and unusual site. J Clin Diagn Res (2014) 0.75
Evolution of differentiated thyroid cancer: a decade of thyroidectomies in a single institution. Eur Thyroid J (2014) 0.75
Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer. Onco Targets Ther (2016) 0.75
Human a-L-fucosidase-1 attenuates the invasive properties of thyroid cancer. Oncotarget (2017) 0.75
Renal metastases as the initial presentation of papillary thyroid carcinoma: A case report and literature review. Mol Clin Oncol (2017) 0.75
Prognosis After Brain Metastasis from Differentiated Thyroid Carcinoma. World J Surg (2016) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst (2005) 5.32
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab (2008) 3.38
Cancer consequences of the Chernobyl accident: 20 years on. J Radiol Prot (2006) 3.03
Europe is iodine deficient. Lancet (2003) 2.99
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract (2010) 2.97
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab (2007) 2.74
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol (2008) 2.70
Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid (2008) 2.65
Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med (2008) 2.47
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol (2013) 2.43
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res (2006) 2.38
Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma. Eur Urol (2008) 2.17
Retracted The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest (2005) 2.09
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab (2007) 1.95
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab (2010) 1.86
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab (2004) 1.82
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab (2002) 1.81
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab (2004) 1.79
Prevalence and functional significance of antipituitary antibodies in patients with autoimmune and non-autoimmune thyroid diseases. J Clin Endocrinol Metab (2007) 1.78
Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg (2005) 1.75
Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab (2004) 1.75
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol (2011) 1.74
Familial dysalbuminemic hyperthyroxinemia: a persistent diagnostic challenge. Clin Chem (2009) 1.71
Minimally invasive video-assisted thyroidectomy for papillary carcinoma: a prospective study of its completeness. Surgery (2002) 1.71
Relative potencies and additivity of perchlorate, thiocyanate, nitrate, and iodide on the inhibition of radioactive iodide uptake by the human sodium iodide symporter. Thyroid (2004) 1.69
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. J Clin Endocrinol Metab (2010) 1.68
The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab (2012) 1.62
Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab (2004) 1.56
Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med (2003) 1.55
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab (2004) 1.52
Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab (2007) 1.51
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab (2010) 1.50
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res (2007) 1.47
Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg (2008) 1.46
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol (2006) 1.45
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Low prevalence of the somatic M918T RET mutation in micro-medullary thyroid cancer. Thyroid (2012) 1.45
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens (2010) 1.43
Prevalence of left ventricular hypertrophy and determinants of left ventricular mass in obese women. High Blood Press Cardiovasc Prev (2012) 1.42
Exacerbation of autoimmune thyroiditis following bilateral adrenalectomy for Cushing's syndrome. Thyroid (2010) 1.39
Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens (2008) 1.39
Ernest L. Mazzaferri, MD, MACP (1936-2013). Thyroid (2013) 1.39
The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab (2014) 1.36
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis. Circ Res (2011) 1.36
Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res (2005) 1.35
Mutations in the selenocysteine insertion sequence-binding protein 2 gene lead to a multisystem selenoprotein deficiency disorder in humans. J Clin Invest (2010) 1.33